EA011816B1 - Белок липокалин - Google Patents

Info

Publication number

EA011816B1

EA011816B1 EA200701918A EA200701918A EA011816B1 EA 011816 B1 EA011816 B1 EA 011816B1 EA 200701918 A EA200701918 A EA 200701918A EA 200701918 A EA200701918 A EA 200701918A EA 011816 B1 EA011816 B1 EA 011816B1

Authority

EA

Eurasian Patent Office

Prior art keywords

polypeptide

nucleic acid

disease

cell

cells

Prior art date

2005-03-08

Links

• Espacenet
• Global Dossier
• Discuss

• 102000019298 Lipocalin Human genes 0.000 title claims abstract description 89
• 108050006654 Lipocalin Proteins 0.000 title claims abstract description 89
• 108090000623 proteins and genes Proteins 0.000 claims abstract description 219
• 102000004169 proteins and genes Human genes 0.000 claims abstract description 120
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 597
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 582
• 229920001184 polypeptide Polymers 0.000 claims description 580
• 210000004027 cell Anatomy 0.000 claims description 211
• 238000000034 method Methods 0.000 claims description 208
• 150000007523 nucleic acids Chemical class 0.000 claims description 141
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 137
• 102000039446 nucleic acids Human genes 0.000 claims description 136
• 108020004707 nucleic acids Proteins 0.000 claims description 136
• 201000010099 disease Diseases 0.000 claims description 107
• 230000014509 gene expression Effects 0.000 claims description 101
• 230000000694 effects Effects 0.000 claims description 87
• 239000012634 fragment Substances 0.000 claims description 86
• 239000000203 mixture Substances 0.000 claims description 68
• 239000013598 vector Substances 0.000 claims description 56
• 239000003446 ligand Substances 0.000 claims description 55
• 150000001413 amino acids Chemical class 0.000 claims description 54
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 43
• 239000000523 sample Substances 0.000 claims description 40
• 238000011282 treatment Methods 0.000 claims description 39
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 32
• 208000035475 disorder Diseases 0.000 claims description 29
• 230000035772 mutation Effects 0.000 claims description 28
• 208000017520 skin disease Diseases 0.000 claims description 27
• 230000015572 biosynthetic process Effects 0.000 claims description 23
• 238000006467 substitution reaction Methods 0.000 claims description 23
• 201000004681 Psoriasis Diseases 0.000 claims description 22
• 239000003814 drug Substances 0.000 claims description 22
• 230000001225 therapeutic effect Effects 0.000 claims description 21
• 238000001514 detection method Methods 0.000 claims description 19
• 208000023275 Autoimmune disease Diseases 0.000 claims description 18
• 206010028980 Neoplasm Diseases 0.000 claims description 18
• 125000000539 amino acid group Chemical group 0.000 claims description 17
• 201000011510 cancer Diseases 0.000 claims description 17
• 230000003321 amplification Effects 0.000 claims description 16
• 238000003199 nucleic acid amplification method Methods 0.000 claims description 16
• 206010012438 Dermatitis atopic Diseases 0.000 claims description 15
• 201000008937 atopic dermatitis Diseases 0.000 claims description 15
• 208000010668 atopic eczema Diseases 0.000 claims description 15
• 238000003745 diagnosis Methods 0.000 claims description 15
• 239000008194 pharmaceutical composition Substances 0.000 claims description 15
• 230000000890 antigenic effect Effects 0.000 claims description 14
• 239000012472 biological sample Substances 0.000 claims description 14
• 238000011161 development Methods 0.000 claims description 14
• 230000003612 virological effect Effects 0.000 claims description 13
• 229960005486 vaccine Drugs 0.000 claims description 12
• 206010009900 Colitis ulcerative Diseases 0.000 claims description 11
• 201000006704 Ulcerative Colitis Diseases 0.000 claims description 11
• 230000001580 bacterial effect Effects 0.000 claims description 11
• 208000011231 Crohn disease Diseases 0.000 claims description 10
• 201000004624 Dermatitis Diseases 0.000 claims description 10
• PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 10
• 230000033228 biological regulation Effects 0.000 claims description 10
• 208000015181 infectious disease Diseases 0.000 claims description 10
• 206010020649 Hyperkeratosis Diseases 0.000 claims description 9
• 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 9
• 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 9
• 201000005962 mycosis fungoides Diseases 0.000 claims description 9
• 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 9
• 206010020751 Hypersensitivity Diseases 0.000 claims description 8
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 8
• 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 8
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
• 230000007815 allergy Effects 0.000 claims description 8
• 208000026278 immune system disease Diseases 0.000 claims description 8
• 201000006417 multiple sclerosis Diseases 0.000 claims description 8
• 239000002853 nucleic acid probe Substances 0.000 claims description 8
• 208000036142 Viral infection Diseases 0.000 claims description 7
• 206010003246 arthritis Diseases 0.000 claims description 7
• 208000006673 asthma Diseases 0.000 claims description 7
• 208000000509 infertility Diseases 0.000 claims description 7
• 230000036512 infertility Effects 0.000 claims description 7
• 231100000535 infertility Toxicity 0.000 claims description 7
• 230000000813 microbial effect Effects 0.000 claims description 7
• 208000010125 myocardial infarction Diseases 0.000 claims description 7
• 230000002062 proliferating effect Effects 0.000 claims description 7
• 230000001850 reproductive effect Effects 0.000 claims description 7
• 206010006187 Breast cancer Diseases 0.000 claims description 6
• 208000026310 Breast neoplasm Diseases 0.000 claims description 6
• 206010012442 Dermatitis contact Diseases 0.000 claims description 6
• 206010048768 Dermatosis Diseases 0.000 claims description 6
• 206010014561 Emphysema Diseases 0.000 claims description 6
• 208000007466 Male Infertility Diseases 0.000 claims description 6
• 206010036774 Proctitis Diseases 0.000 claims description 6
• 206010047571 Visual impairment Diseases 0.000 claims description 6
• 230000001154 acute effect Effects 0.000 claims description 6
• 208000026935 allergic disease Diseases 0.000 claims description 6
• 208000010247 contact dermatitis Diseases 0.000 claims description 6
• 239000013068 control sample Substances 0.000 claims description 6
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 6
• 229910052737 gold Inorganic materials 0.000 claims description 6
• 239000010931 gold Substances 0.000 claims description 6
• 210000000653 nervous system Anatomy 0.000 claims description 6
• 208000011580 syndromic disease Diseases 0.000 claims description 6
• 238000002560 therapeutic procedure Methods 0.000 claims description 6
• 230000029663 wound healing Effects 0.000 claims description 6
• 208000035143 Bacterial infection Diseases 0.000 claims description 5
• 206010004146 Basal cell carcinoma Diseases 0.000 claims description 5
• 206010009137 Chronic sinusitis Diseases 0.000 claims description 5
• 208000037845 Cutaneous squamous cell carcinoma Diseases 0.000 claims description 5
• 208000000571 Fibrocystic breast disease Diseases 0.000 claims description 5
• 206010017533 Fungal infection Diseases 0.000 claims description 5
• 208000015023 Graves' disease Diseases 0.000 claims description 5
• 208000001204 Hashimoto Disease Diseases 0.000 claims description 5
• 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 5
• 208000031888 Mycoses Diseases 0.000 claims description 5
• 208000001140 Night Blindness Diseases 0.000 claims description 5
• 206010062237 Renal impairment Diseases 0.000 claims description 5
• 206010039085 Rhinitis allergic Diseases 0.000 claims description 5
• 201000010105 allergic rhinitis Diseases 0.000 claims description 5
• 208000022362 bacterial infectious disease Diseases 0.000 claims description 5
• 208000027157 chronic rhinosinusitis Diseases 0.000 claims description 5
• 230000005977 kidney dysfunction Effects 0.000 claims description 5
• 201000008350 membranous glomerulonephritis Diseases 0.000 claims description 5
• 229910052759 nickel Inorganic materials 0.000 claims description 5
• 230000005855 radiation Effects 0.000 claims description 5
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
• 201000010106 skin squamous cell carcinoma Diseases 0.000 claims description 5
• 206010043778 thyroiditis Diseases 0.000 claims description 5
• 230000009385 viral infection Effects 0.000 claims description 5
• 206010018364 Glomerulonephritis Diseases 0.000 claims description 4
• 208000003807 Graves Disease Diseases 0.000 claims description 4
• 208000005176 Hepatitis C Diseases 0.000 claims description 4
• 208000001126 Keratosis Diseases 0.000 claims description 4
• 206010046851 Uveitis Diseases 0.000 claims description 4
• 230000000172 allergic effect Effects 0.000 claims description 4
• 210000005252 bulbus oculi Anatomy 0.000 claims description 4
• 230000008859 change Effects 0.000 claims description 4
• 230000001434 glomerular Effects 0.000 claims description 4
• 230000004968 inflammatory condition Effects 0.000 claims description 4
• 201000011486 lichen planus Diseases 0.000 claims description 4
• 238000012544 monitoring process Methods 0.000 claims description 4
• 208000003619 porokeratosis Diseases 0.000 claims description 4
• 201000008171 proliferative glomerulonephritis Diseases 0.000 claims description 4
• 201000000306 sarcoidosis Diseases 0.000 claims description 4
• 206010012601 diabetes mellitus Diseases 0.000 claims description 3
• 206010052428 Wound Diseases 0.000 claims 1
• 208000027418 Wounds and injury Diseases 0.000 claims 1
• 230000035876 healing Effects 0.000 claims 1
• 108090000144 Human Proteins Proteins 0.000 abstract description 2
• 102000003839 Human Proteins Human genes 0.000 abstract description 2
• 150000001875 compounds Chemical class 0.000 description 121
• 235000018102 proteins Nutrition 0.000 description 116
• 238000012360 testing method Methods 0.000 description 112
• 108020004414 DNA Proteins 0.000 description 84
• 238000003752 polymerase chain reaction Methods 0.000 description 81
• 241000282414 Homo sapiens Species 0.000 description 63
• 235000001014 amino acid Nutrition 0.000 description 61
• 102000004127 Cytokines Human genes 0.000 description 55
• 108090000695 Cytokines Proteins 0.000 description 55
• 238000009739 binding Methods 0.000 description 51
• 229940024606 amino acid Drugs 0.000 description 50
• 230000027455 binding Effects 0.000 description 50
• 239000002299 complementary DNA Substances 0.000 description 46
• 238000004458 analytical method Methods 0.000 description 45
• 239000000047 product Substances 0.000 description 44
• 235000014304 histidine Nutrition 0.000 description 43
• 239000013612 plasmid Substances 0.000 description 43
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 41
• 239000005557 antagonist Substances 0.000 description 34
• 238000012216 screening Methods 0.000 description 34
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 30
• 238000006243 chemical reaction Methods 0.000 description 30
• 239000011541 reaction mixture Substances 0.000 description 30
• 125000003729 nucleotide group Chemical group 0.000 description 29
• 210000001519 tissue Anatomy 0.000 description 29
• 238000004519 manufacturing process Methods 0.000 description 28
• 239000002773 nucleotide Substances 0.000 description 28
• 230000028327 secretion Effects 0.000 description 27
• 239000000556 agonist Substances 0.000 description 26
• 230000006870 function Effects 0.000 description 24
• 230000001105 regulatory effect Effects 0.000 description 24
• 238000003556 assay Methods 0.000 description 23
• 108020004999 messenger RNA Proteins 0.000 description 23
• 238000000746 purification Methods 0.000 description 23
• 238000010367 cloning Methods 0.000 description 21
• 108020001507 fusion proteins Proteins 0.000 description 21
• 102000037865 fusion proteins Human genes 0.000 description 21
• 102000004190 Enzymes Human genes 0.000 description 20
• 108090000790 Enzymes Proteins 0.000 description 20
• 229940088598 enzyme Drugs 0.000 description 20
• 238000009396 hybridization Methods 0.000 description 20
• 230000004048 modification Effects 0.000 description 20
• 238000012986 modification Methods 0.000 description 20
• 239000000872 buffer Substances 0.000 description 19
• 239000003795 chemical substances by application Substances 0.000 description 19
• 238000012163 sequencing technique Methods 0.000 description 19
• 230000008569 process Effects 0.000 description 18
• 238000005755 formation reaction Methods 0.000 description 17
• 210000001744 T-lymphocyte Anatomy 0.000 description 16
• 102000005962 receptors Human genes 0.000 description 16
• 108020003175 receptors Proteins 0.000 description 16
• 230000004044 response Effects 0.000 description 16
• 229940079593 drug Drugs 0.000 description 15
• 230000035755 proliferation Effects 0.000 description 15
• 241001465754 Metazoa Species 0.000 description 14
• 108091034117 Oligonucleotide Proteins 0.000 description 14
• -1 cis-retinoids Chemical compound 0.000 description 14
• 238000002360 preparation method Methods 0.000 description 14
• 239000003153 chemical reaction reagent Substances 0.000 description 13
• 230000001965 increasing effect Effects 0.000 description 13
• 239000000758 substrate Substances 0.000 description 13
• 241000196324 Embryophyta Species 0.000 description 12
• 230000000295 complement effect Effects 0.000 description 12
• 230000018109 developmental process Effects 0.000 description 12
• 238000003780 insertion Methods 0.000 description 12
• 230000037431 insertion Effects 0.000 description 12
• 239000003550 marker Substances 0.000 description 12
• 239000011159 matrix material Substances 0.000 description 12
• 210000003491 skin Anatomy 0.000 description 12
• 239000000126 substance Substances 0.000 description 12
• 239000006228 supernatant Substances 0.000 description 12
• 108091026890 Coding region Proteins 0.000 description 11
• 241000124008 Mammalia Species 0.000 description 11
• 239000011543 agarose gel Substances 0.000 description 11
• FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 11
• 210000000170 cell membrane Anatomy 0.000 description 11
• 210000004379 membrane Anatomy 0.000 description 11
• 239000012528 membrane Substances 0.000 description 11
• 238000002741 site-directed mutagenesis Methods 0.000 description 11
• 239000007787 solid Substances 0.000 description 11
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 10
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 10
• 230000004913 activation Effects 0.000 description 10
• 230000004071 biological effect Effects 0.000 description 10
• 238000010790 dilution Methods 0.000 description 10
• 239000012895 dilution Substances 0.000 description 10
• 230000002209 hydrophobic effect Effects 0.000 description 10
• 238000011534 incubation Methods 0.000 description 10
• 239000000243 solution Substances 0.000 description 10
• 108010076504 Protein Sorting Signals Proteins 0.000 description 9
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 9
• 230000000692 anti-sense effect Effects 0.000 description 9
• 239000000427 antigen Substances 0.000 description 9
• 108091007433 antigens Proteins 0.000 description 9
• 102000036639 antigens Human genes 0.000 description 9
• 238000001574 biopsy Methods 0.000 description 9
• 238000004113 cell culture Methods 0.000 description 9
• 238000005516 engineering process Methods 0.000 description 9
• 239000013604 expression vector Substances 0.000 description 9
• 239000003112 inhibitor Substances 0.000 description 9
• 239000002609 medium Substances 0.000 description 9
• 210000000440 neutrophil Anatomy 0.000 description 9
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
• 238000012545 processing Methods 0.000 description 9
• 238000003786 synthesis reaction Methods 0.000 description 9
• 238000013519 translation Methods 0.000 description 9
• 108020004705 Codon Proteins 0.000 description 8
• 238000002965 ELISA Methods 0.000 description 8
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
• 239000000969 carrier Substances 0.000 description 8
• 239000003937 drug carrier Substances 0.000 description 8
• 238000010438 heat treatment Methods 0.000 description 8
• 102000040430 polynucleotide Human genes 0.000 description 8
• 108091033319 polynucleotide Proteins 0.000 description 8
• 239000002157 polynucleotide Substances 0.000 description 8
• 238000007390 skin biopsy Methods 0.000 description 8
• 239000008223 sterile water Substances 0.000 description 8
• 210000004291 uterus Anatomy 0.000 description 8
• 101100519158 Arabidopsis thaliana PCR2 gene Proteins 0.000 description 7
• 108090000994 Catalytic RNA Proteins 0.000 description 7
• 102000053642 Catalytic RNA Human genes 0.000 description 7
• 101150102573 PCR1 gene Proteins 0.000 description 7
• 229960000723 ampicillin Drugs 0.000 description 7
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 7
• 239000011575 calcium Substances 0.000 description 7
• 239000013592 cell lysate Substances 0.000 description 7
• 210000000349 chromosome Anatomy 0.000 description 7
• 239000000499 gel Substances 0.000 description 7
• 230000013595 glycosylation Effects 0.000 description 7
• 238000006206 glycosylation reaction Methods 0.000 description 7
• 238000002955 isolation Methods 0.000 description 7
• 201000010260 leiomyoma Diseases 0.000 description 7
• 239000000463 material Substances 0.000 description 7
• 210000000274 microglia Anatomy 0.000 description 7
• 239000000816 peptidomimetic Substances 0.000 description 7
• 238000003127 radioimmunoassay Methods 0.000 description 7
• 108091092562 ribozyme Proteins 0.000 description 7
• 210000002966 serum Anatomy 0.000 description 7
• 230000000638 stimulation Effects 0.000 description 7
• FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 6
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
• 241000282412 Homo Species 0.000 description 6
• 239000008049 TAE buffer Substances 0.000 description 6
• 230000002159 abnormal effect Effects 0.000 description 6
• HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 6
• 150000003862 amino acid derivatives Chemical class 0.000 description 6
• 238000013459 approach Methods 0.000 description 6
• 230000030833 cell death Effects 0.000 description 6
• 230000007423 decrease Effects 0.000 description 6
• 238000012217 deletion Methods 0.000 description 6
• 230000037430 deletion Effects 0.000 description 6
• 230000004069 differentiation Effects 0.000 description 6
• 210000001508 eye Anatomy 0.000 description 6
• 238000001415 gene therapy Methods 0.000 description 6
• 230000002068 genetic effect Effects 0.000 description 6
• 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 6
• 230000002163 immunogen Effects 0.000 description 6
• 230000005764 inhibitory process Effects 0.000 description 6
• 150000002632 lipids Chemical class 0.000 description 6
• 210000004698 lymphocyte Anatomy 0.000 description 6
• 210000002540 macrophage Anatomy 0.000 description 6
• 210000004962 mammalian cell Anatomy 0.000 description 6
• 210000001616 monocyte Anatomy 0.000 description 6
• 238000012552 review Methods 0.000 description 6
• 230000035939 shock Effects 0.000 description 6
• 238000010561 standard procedure Methods 0.000 description 6
• 239000000725 suspension Substances 0.000 description 6
• 239000003826 tablet Substances 0.000 description 6
• 238000013518 transcription Methods 0.000 description 6
• 230000035897 transcription Effects 0.000 description 6
• 230000032258 transport Effects 0.000 description 6
• 238000001712 DNA sequencing Methods 0.000 description 5
• 241000238631 Hexapoda Species 0.000 description 5
• 241000699666 Mus <mouse, genus> Species 0.000 description 5
• 241000699670 Mus sp. Species 0.000 description 5
• 238000012408 PCR amplification Methods 0.000 description 5
• 102000006382 Ribonucleases Human genes 0.000 description 5
• 108010083644 Ribonucleases Proteins 0.000 description 5
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
• 230000032683 aging Effects 0.000 description 5
• 230000000845 anti-microbial effect Effects 0.000 description 5
• 230000008827 biological function Effects 0.000 description 5
• 210000001124 body fluid Anatomy 0.000 description 5
• 210000004899 c-terminal region Anatomy 0.000 description 5
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 5
• 231100000673 dose–response relationship Toxicity 0.000 description 5
• 210000002503 granulosa cell Anatomy 0.000 description 5
• 230000003993 interaction Effects 0.000 description 5
• 229930027917 kanamycin Natural products 0.000 description 5
• 229960000318 kanamycin Drugs 0.000 description 5
• SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 5
• 229930182823 kanamycin A Natural products 0.000 description 5
• 239000007788 liquid Substances 0.000 description 5
• 210000001672 ovary Anatomy 0.000 description 5
• 230000001575 pathological effect Effects 0.000 description 5
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
• 230000008707 rearrangement Effects 0.000 description 5
• 229960003471 retinol Drugs 0.000 description 5
• 235000020944 retinol Nutrition 0.000 description 5
• 239000011607 retinol Substances 0.000 description 5
• 230000002441 reversible effect Effects 0.000 description 5
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 5
• 230000009261 transgenic effect Effects 0.000 description 5
• VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
• 241000894006 Bacteria Species 0.000 description 4
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
• 102000014914 Carrier Proteins Human genes 0.000 description 4
• 102000053602 DNA Human genes 0.000 description 4
• 238000009007 Diagnostic Kit Methods 0.000 description 4
• 108010067770 Endopeptidase K Proteins 0.000 description 4
• 102000016359 Fibronectins Human genes 0.000 description 4
• 108010067306 Fibronectins Proteins 0.000 description 4
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
• 102000004240 Glycodelin Human genes 0.000 description 4
• 108010081520 Glycodelin Proteins 0.000 description 4
• 102100034343 Integrase Human genes 0.000 description 4
• 239000006142 Luria-Bertani Agar Substances 0.000 description 4
• 239000004698 Polyethylene Substances 0.000 description 4
• 108010029485 Protein Isoforms Proteins 0.000 description 4
• 102000001708 Protein Isoforms Human genes 0.000 description 4
• 239000007984 Tris EDTA buffer Substances 0.000 description 4
• 241000700605 Viruses Species 0.000 description 4
• 238000007792 addition Methods 0.000 description 4
• 238000001042 affinity chromatography Methods 0.000 description 4
• 238000010171 animal model Methods 0.000 description 4
• 238000003491 array Methods 0.000 description 4
• 238000013528 artificial neural network Methods 0.000 description 4
• 210000004369 blood Anatomy 0.000 description 4
• 239000008280 blood Substances 0.000 description 4
• 239000010839 body fluid Substances 0.000 description 4
• 229910052791 calcium Inorganic materials 0.000 description 4
• 230000004663 cell proliferation Effects 0.000 description 4
• 230000001413 cellular effect Effects 0.000 description 4
• 238000005119 centrifugation Methods 0.000 description 4
• 238000004587 chromatography analysis Methods 0.000 description 4
• 238000003776 cleavage reaction Methods 0.000 description 4
• 238000002405 diagnostic procedure Methods 0.000 description 4
• 239000003623 enhancer Substances 0.000 description 4
• 229960005309 estradiol Drugs 0.000 description 4
• 229930182833 estradiol Natural products 0.000 description 4
• 238000002474 experimental method Methods 0.000 description 4
• 239000012530 fluid Substances 0.000 description 4
• 239000002955 immunomodulating agent Substances 0.000 description 4
• 229940121354 immunomodulator Drugs 0.000 description 4
• 239000012535 impurity Substances 0.000 description 4
• 230000006698 induction Effects 0.000 description 4
• 210000003734 kidney Anatomy 0.000 description 4
• 238000002372 labelling Methods 0.000 description 4
• 210000000265 leukocyte Anatomy 0.000 description 4
• 230000004807 localization Effects 0.000 description 4
• 230000007246 mechanism Effects 0.000 description 4
• 230000001404 mediated effect Effects 0.000 description 4
• PKAHQJNJPDVTDP-UHFFFAOYSA-N methyl cyclopropanecarboxylate Chemical compound COC(=O)C1CC1 PKAHQJNJPDVTDP-UHFFFAOYSA-N 0.000 description 4
• 210000002307 prostate Anatomy 0.000 description 4
• 238000000159 protein binding assay Methods 0.000 description 4
• 230000006798 recombination Effects 0.000 description 4
• 238000005215 recombination Methods 0.000 description 4
• 238000011160 research Methods 0.000 description 4
• 210000003079 salivary gland Anatomy 0.000 description 4
• 230000007017 scission Effects 0.000 description 4
• 229940124597 therapeutic agent Drugs 0.000 description 4
• RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
• 230000009466 transformation Effects 0.000 description 4
• 241000701447 unidentified baculovirus Species 0.000 description 4
• 241001515965 unidentified phage Species 0.000 description 4
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
• 102000005606 Activins Human genes 0.000 description 3
• 108010059616 Activins Proteins 0.000 description 3
• 101100457021 Caenorhabditis elegans mag-1 gene Proteins 0.000 description 3
• 241000283707 Capra Species 0.000 description 3
• 108020004635 Complementary DNA Proteins 0.000 description 3
• 201000009273 Endometriosis Diseases 0.000 description 3
• 102100029727 Enteropeptidase Human genes 0.000 description 3
• 108010013369 Enteropeptidase Proteins 0.000 description 3
• 108700024394 Exon Proteins 0.000 description 3
• 244000068988 Glycine max Species 0.000 description 3
• 235000010469 Glycine max Nutrition 0.000 description 3
• 108060003951 Immunoglobulin Proteins 0.000 description 3
• 101710203526 Integrase Proteins 0.000 description 3
• 102000003814 Interleukin-10 Human genes 0.000 description 3
• 108090000174 Interleukin-10 Proteins 0.000 description 3
• 102000004388 Interleukin-4 Human genes 0.000 description 3
• 108090000978 Interleukin-4 Proteins 0.000 description 3
• 102100039897 Interleukin-5 Human genes 0.000 description 3
• 108010002616 Interleukin-5 Proteins 0.000 description 3
• 108060001084 Luciferase Proteins 0.000 description 3
• 101100067996 Mus musculus Gbp1 gene Proteins 0.000 description 3
• 241000283973 Oryctolagus cuniculus Species 0.000 description 3
• 102000004264 Osteopontin Human genes 0.000 description 3
• 108010081689 Osteopontin Proteins 0.000 description 3
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
• 230000006052 T cell proliferation Effects 0.000 description 3
• 206010046798 Uterine leiomyoma Diseases 0.000 description 3
• 239000002253 acid Substances 0.000 description 3
• 239000000488 activin Substances 0.000 description 3
• 210000004100 adrenal gland Anatomy 0.000 description 3
• 108091008324 binding proteins Proteins 0.000 description 3
• 210000004556 brain Anatomy 0.000 description 3
• 238000010804 cDNA synthesis Methods 0.000 description 3
• 238000012937 correction Methods 0.000 description 3
• NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 3
• 230000002950 deficient Effects 0.000 description 3
• 229960000633 dextran sulfate Drugs 0.000 description 3
• 239000002552 dosage form Substances 0.000 description 3
• 239000000975 dye Substances 0.000 description 3
• 210000004696 endometrium Anatomy 0.000 description 3
• 210000000981 epithelium Anatomy 0.000 description 3
• 239000000284 extract Substances 0.000 description 3
• 239000003862 glucocorticoid Substances 0.000 description 3
• 235000011187 glycerol Nutrition 0.000 description 3
• 210000003714 granulocyte Anatomy 0.000 description 3
• 230000012010 growth Effects 0.000 description 3
• 210000005260 human cell Anatomy 0.000 description 3
• 210000003917 human chromosome Anatomy 0.000 description 3
• 230000028993 immune response Effects 0.000 description 3
• 238000003018 immunoassay Methods 0.000 description 3
• 102000018358 immunoglobulin Human genes 0.000 description 3
• 230000001939 inductive effect Effects 0.000 description 3
• 238000002347 injection Methods 0.000 description 3
• 239000007924 injection Substances 0.000 description 3
• 229940076144 interleukin-10 Drugs 0.000 description 3
• 229940028885 interleukin-4 Drugs 0.000 description 3
• 229940100602 interleukin-5 Drugs 0.000 description 3
• 230000003834 intracellular effect Effects 0.000 description 3
• 238000007912 intraperitoneal administration Methods 0.000 description 3
• 239000002502 liposome Substances 0.000 description 3
• 238000013507 mapping Methods 0.000 description 3
• 238000005259 measurement Methods 0.000 description 3
• 230000005012 migration Effects 0.000 description 3
• 238000013508 migration Methods 0.000 description 3
• 210000005087 mononuclear cell Anatomy 0.000 description 3
• 230000002018 overexpression Effects 0.000 description 3
• 230000035515 penetration Effects 0.000 description 3
• 210000005259 peripheral blood Anatomy 0.000 description 3
• 239000011886 peripheral blood Substances 0.000 description 3
• 230000001817 pituitary effect Effects 0.000 description 3
• 230000001323 posttranslational effect Effects 0.000 description 3
• 238000004321 preservation Methods 0.000 description 3
• 230000000069 prophylactic effect Effects 0.000 description 3
• 150000003180 prostaglandins Chemical class 0.000 description 3
• 238000003753 real-time PCR Methods 0.000 description 3
• 238000003757 reverse transcription PCR Methods 0.000 description 3
• 150000003839 salts Chemical class 0.000 description 3
• 238000007423 screening assay Methods 0.000 description 3
• 230000003248 secreting effect Effects 0.000 description 3
• 241000894007 species Species 0.000 description 3
• 230000004936 stimulating effect Effects 0.000 description 3
• 210000002536 stromal cell Anatomy 0.000 description 3
• 238000007920 subcutaneous administration Methods 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• 210000001550 testis Anatomy 0.000 description 3
• 238000001890 transfection Methods 0.000 description 3
• 230000001131 transforming effect Effects 0.000 description 3
• 210000002993 trophoblast Anatomy 0.000 description 3
• 230000003827 upregulation Effects 0.000 description 3
• 239000011534 wash buffer Substances 0.000 description 3
• 238000005406 washing Methods 0.000 description 3
• 210000005253 yeast cell Anatomy 0.000 description 3
• SMWADGDVGCZIGK-AXDSSHIGSA-N (2s)-5-phenylpyrrolidine-2-carboxylic acid Chemical compound N1[C@H](C(=O)O)CCC1C1=CC=CC=C1 SMWADGDVGCZIGK-AXDSSHIGSA-N 0.000 description 2
• FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 2
• 241000972773 Aulopiformes Species 0.000 description 2
• 241000193830 Bacillus <bacterium> Species 0.000 description 2
• 241000282472 Canis lupus familiaris Species 0.000 description 2
• 108010001857 Cell Surface Receptors Proteins 0.000 description 2
• 102000000844 Cell Surface Receptors Human genes 0.000 description 2
• 241000282693 Cercopithecidae Species 0.000 description 2
• IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
• 108010036949 Cyclosporine Proteins 0.000 description 2
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
• 108060002716 Exonuclease Proteins 0.000 description 2
• 201000008808 Fibrosarcoma Diseases 0.000 description 2
• 229920001917 Ficoll Polymers 0.000 description 2
• 102000013382 Gelatinases Human genes 0.000 description 2
• 108010026132 Gelatinases Proteins 0.000 description 2
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
• 229930182816 L-glutamine Natural products 0.000 description 2
• 102000003752 Lipocalin 1 Human genes 0.000 description 2
• 108010057281 Lipocalin 1 Proteins 0.000 description 2
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
• 239000004472 Lysine Substances 0.000 description 2
• 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
• 241000948268 Meda Species 0.000 description 2
• 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 2
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• ORNBQBCIOKFOEO-YQUGOWONSA-N Pregnenolone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1 ORNBQBCIOKFOEO-YQUGOWONSA-N 0.000 description 2
• REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
• 239000013614 RNA sample Substances 0.000 description 2
• 241000700159 Rattus Species 0.000 description 2
• 108020004511 Recombinant DNA Proteins 0.000 description 2
• 108700008625 Reporter Genes Proteins 0.000 description 2
• 102100037968 Ribonuclease inhibitor Human genes 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• 238000012300 Sequence Analysis Methods 0.000 description 2
• 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
• 108020004682 Single-Stranded DNA Proteins 0.000 description 2
• 241000282887 Suidae Species 0.000 description 2
• 102000002933 Thioredoxin Human genes 0.000 description 2
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
• IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 2
• ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
• 102100025836 Voltage-dependent L-type calcium channel subunit beta-4 Human genes 0.000 description 2
• 101710176693 Voltage-dependent L-type calcium channel subunit beta-4 Proteins 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 230000002730 additional effect Effects 0.000 description 2
• 230000002411 adverse Effects 0.000 description 2
• 239000004599 antimicrobial Substances 0.000 description 2
• 210000003719 b-lymphocyte Anatomy 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 208000030270 breast disease Diseases 0.000 description 2
• 230000003491 cAMP production Effects 0.000 description 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
• 238000012512 characterization method Methods 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 229960001265 ciclosporin Drugs 0.000 description 2
• 238000004140 cleaning Methods 0.000 description 2
• 210000001072 colon Anatomy 0.000 description 2
• 238000012875 competitive assay Methods 0.000 description 2
• 238000004132 cross linking Methods 0.000 description 2
• VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
• 229940095074 cyclic amp Drugs 0.000 description 2
• 229930182912 cyclosporin Natural products 0.000 description 2
• 235000018417 cysteine Nutrition 0.000 description 2
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
• 210000004292 cytoskeleton Anatomy 0.000 description 2
• HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
• 230000016117 decidualization Effects 0.000 description 2
• 238000004925 denaturation Methods 0.000 description 2
• 230000036425 denaturation Effects 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 238000007877 drug screening Methods 0.000 description 2
• 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
• 210000002615 epidermis Anatomy 0.000 description 2
• 210000002919 epithelial cell Anatomy 0.000 description 2
• 101150070966 eta gene Proteins 0.000 description 2
• 210000003527 eukaryotic cell Anatomy 0.000 description 2
• 102000013165 exonuclease Human genes 0.000 description 2
• 230000004720 fertilization Effects 0.000 description 2
• 239000007850 fluorescent dye Substances 0.000 description 2
• UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
• 210000002443 helper t lymphocyte Anatomy 0.000 description 2
• 125000005842 heteroatom Chemical group 0.000 description 2
• 210000004408 hybridoma Anatomy 0.000 description 2
• 239000001257 hydrogen Substances 0.000 description 2
• 229910052739 hydrogen Inorganic materials 0.000 description 2
• 230000007062 hydrolysis Effects 0.000 description 2
• 238000006460 hydrolysis reaction Methods 0.000 description 2
• 210000003405 ileum Anatomy 0.000 description 2
• 230000002519 immonomodulatory effect Effects 0.000 description 2
• 230000002584 immunomodulator Effects 0.000 description 2
• 238000002513 implantation Methods 0.000 description 2
• 230000008595 infiltration Effects 0.000 description 2
• 238000001764 infiltration Methods 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• 238000011081 inoculation Methods 0.000 description 2
• 230000000968 intestinal effect Effects 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
• 150000002515 isoflavone derivatives Chemical class 0.000 description 2
• 235000008696 isoflavones Nutrition 0.000 description 2
• MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
• 230000003902 lesion Effects 0.000 description 2
• 238000007834 ligase chain reaction Methods 0.000 description 2
• 150000002634 lipophilic molecules Chemical class 0.000 description 2
• 230000013011 mating Effects 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 150000002739 metals Chemical class 0.000 description 2
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
• 239000003226 mitogen Substances 0.000 description 2
• 238000007857 nested PCR Methods 0.000 description 2
• 230000007935 neutral effect Effects 0.000 description 2
• 230000003472 neutralizing effect Effects 0.000 description 2
• 210000000287 oocyte Anatomy 0.000 description 2
• 238000004806 packaging method and process Methods 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• 239000002831 pharmacologic agent Substances 0.000 description 2
• 235000002378 plant sterols Nutrition 0.000 description 2
• 210000002381 plasma Anatomy 0.000 description 2
• 201000010065 polycystic ovary syndrome Diseases 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 230000035935 pregnancy Effects 0.000 description 2
• 229960000249 pregnenolone Drugs 0.000 description 2
• ORNBQBCIOKFOEO-QGVNFLHTSA-N pregnenolone Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 ORNBQBCIOKFOEO-QGVNFLHTSA-N 0.000 description 2
• 239000006041 probiotic Substances 0.000 description 2
• 235000018291 probiotics Nutrition 0.000 description 2
• 238000004393 prognosis Methods 0.000 description 2
• 238000001742 protein purification Methods 0.000 description 2
• 230000006337 proteolytic cleavage Effects 0.000 description 2
• ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
• BBNQQADTFFCFGB-UHFFFAOYSA-N purpurin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC(O)=C3C(=O)C2=C1 BBNQQADTFFCFGB-UHFFFAOYSA-N 0.000 description 2
• 239000011535 reaction buffer Substances 0.000 description 2
• 239000000018 receptor agonist Substances 0.000 description 2
• 229940044601 receptor agonist Drugs 0.000 description 2
• 230000002829 reductive effect Effects 0.000 description 2
• 230000008085 renal dysfunction Effects 0.000 description 2
• 108091010987 retinoic acid binding proteins Proteins 0.000 description 2
• 102000003702 retinoic acid receptors Human genes 0.000 description 2
• 108090000064 retinoic acid receptors Proteins 0.000 description 2
• 102000029752 retinol binding Human genes 0.000 description 2
• 108091000053 retinol binding Proteins 0.000 description 2
• QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 2
• 230000001177 retroviral effect Effects 0.000 description 2
• 235000019515 salmon Nutrition 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• 150000003384 small molecules Chemical class 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• 239000001509 sodium citrate Substances 0.000 description 2
• 239000001488 sodium phosphate Substances 0.000 description 2
• 229910000162 sodium phosphate Inorganic materials 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 230000009870 specific binding Effects 0.000 description 2
• 238000001228 spectrum Methods 0.000 description 2
• 230000010009 steroidogenesis Effects 0.000 description 2
• 210000002784 stomach Anatomy 0.000 description 2
• 229960005322 streptomycin Drugs 0.000 description 2
• 235000000346 sugar Nutrition 0.000 description 2
• 231100000617 superantigen Toxicity 0.000 description 2
• 230000001629 suppression Effects 0.000 description 2
• 230000004083 survival effect Effects 0.000 description 2
• 229940037128 systemic glucocorticoids Drugs 0.000 description 2
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
• 108060008226 thioredoxin Proteins 0.000 description 2
• 229940094937 thioredoxin Drugs 0.000 description 2
• 238000012546 transfer Methods 0.000 description 2
• 230000005945 translocation Effects 0.000 description 2
• HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
• 229940038773 trisodium citrate Drugs 0.000 description 2
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
• 241000701161 unidentified adenovirus Species 0.000 description 2
• 210000002700 urine Anatomy 0.000 description 2
• 208000010579 uterine corpus leiomyoma Diseases 0.000 description 2
• 201000007954 uterine fibroid Diseases 0.000 description 2
• 238000012800 visualization Methods 0.000 description 2
• 229940088594 vitamin Drugs 0.000 description 2
• 229930003231 vitamin Natural products 0.000 description 2
• 235000013343 vitamin Nutrition 0.000 description 2
• 239000011782 vitamin Substances 0.000 description 2
• 150000003722 vitamin derivatives Chemical class 0.000 description 2
• 238000001262 western blot Methods 0.000 description 2
• PSQYTAPXSHCGMF-BQYQJAHWSA-N β-ionone Chemical compound CC(=O)\C=C\C1=C(C)CCCC1(C)C PSQYTAPXSHCGMF-BQYQJAHWSA-N 0.000 description 2
• SFEOKXHPFMOVRM-UHFFFAOYSA-N (+)-(S)-gamma-ionone Natural products CC(=O)C=CC1C(=C)CCCC1(C)C SFEOKXHPFMOVRM-UHFFFAOYSA-N 0.000 description 1
• WAMWSIDTKSNDCU-ZETCQYMHSA-N (2s)-2-azaniumyl-2-cyclohexylacetate Chemical compound OC(=O)[C@@H](N)C1CCCCC1 WAMWSIDTKSNDCU-ZETCQYMHSA-N 0.000 description 1
• HBOMLICNUCNMMY-KJFJCRTCSA-N 1-[(4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-KJFJCRTCSA-N 0.000 description 1
• UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
• 101150016096 17 gene Proteins 0.000 description 1
• OMGHIGVFLOPEHJ-UHFFFAOYSA-N 2,5-dihydro-1h-pyrrol-1-ium-2-carboxylate Chemical compound OC(=O)C1NCC=C1 OMGHIGVFLOPEHJ-UHFFFAOYSA-N 0.000 description 1
• GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
• VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
• ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 229930024421 Adenine Natural products 0.000 description 1
• GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
• 102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 1
• 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
• 206010067484 Adverse reaction Diseases 0.000 description 1
• 108700028369 Alleles Proteins 0.000 description 1
• 206010027654 Allergic conditions Diseases 0.000 description 1
• 108020004491 Antisense DNA Proteins 0.000 description 1
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
• 101710147666 Aphrodisin Proteins 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
• 238000012935 Averaging Methods 0.000 description 1
• 208000023328 Basedow disease Diseases 0.000 description 1
• 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
• 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 1
• 102100021257 Beta-secretase 1 Human genes 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 101000800130 Bos taurus Thyroglobulin Proteins 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 101100291853 Caenorhabditis briggsae uba-4 gene Proteins 0.000 description 1
• 101100291854 Caenorhabditis elegans moc-3 gene Proteins 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• 241000701489 Cauliflower mosaic virus Species 0.000 description 1
• 102000009410 Chemokine receptor Human genes 0.000 description 1
• 108050000299 Chemokine receptor Proteins 0.000 description 1
• 206010008631 Cholera Diseases 0.000 description 1
• 108091033380 Coding strand Proteins 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
• 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
• 108010062580 Concanavalin A Proteins 0.000 description 1
• 229920000742 Cotton Polymers 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• 229930105110 Cyclosporin A Natural products 0.000 description 1
• UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
• DZLNHFMRPBPULJ-GSVOUGTGSA-N D-thioproline Chemical compound OC(=O)[C@H]1CSCN1 DZLNHFMRPBPULJ-GSVOUGTGSA-N 0.000 description 1
• 108010017826 DNA Polymerase I Proteins 0.000 description 1
• 102000004594 DNA Polymerase I Human genes 0.000 description 1
• 230000004568 DNA-binding Effects 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 206010061819 Disease recurrence Diseases 0.000 description 1
• 108010042407 Endonucleases Proteins 0.000 description 1
• 102000004533 Endonucleases Human genes 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 241000402754 Erythranthe moschata Species 0.000 description 1
• 241000701959 Escherichia virus Lambda Species 0.000 description 1
• 108700039887 Essential Genes Proteins 0.000 description 1
• 108010008165 Etanercept Proteins 0.000 description 1
• 108050001049 Extracellular proteins Proteins 0.000 description 1
• 108010074860 Factor Xa Proteins 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 102000006771 Gonadotropins Human genes 0.000 description 1
• 108010086677 Gonadotropins Proteins 0.000 description 1
• 241000219146 Gossypium Species 0.000 description 1
• 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
• 101710154606 Hemagglutinin Proteins 0.000 description 1
• 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
• 101000929799 Homo sapiens Acyl-CoA-binding protein Proteins 0.000 description 1
• 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 description 1
• 101000862396 Homo sapiens Follicle-stimulating hormone receptor Proteins 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
• 241000257303 Hymenoptera Species 0.000 description 1
• 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
• 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 229930010555 Inosine Natural products 0.000 description 1
• UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
• 108091092195 Intron Proteins 0.000 description 1
• WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
• WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
• ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• 102000023108 LH Receptors Human genes 0.000 description 1
• 108010011942 LH Receptors Proteins 0.000 description 1
• 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
• 239000005089 Luciferase Substances 0.000 description 1
• 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
• 101710127797 Macrophage colony-stimulating factor 1 Proteins 0.000 description 1
• 244000141359 Malus pumila Species 0.000 description 1
• 102000016943 Muramidase Human genes 0.000 description 1
• 108010014251 Muramidase Proteins 0.000 description 1
• 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
• SNFYYXUGUBUECJ-UHFFFAOYSA-N N-{4-[2-ethyl-1-(1,2,4-triazol-1-yl)butyl]phenyl}-1,3-benzothiazol-2-amine Chemical compound C=1C=C(NC=2SC3=CC=CC=C3N=2)C=CC=1C(C(CC)CC)N1C=NC=N1 SNFYYXUGUBUECJ-UHFFFAOYSA-N 0.000 description 1
• 229930193140 Neomycin Natural products 0.000 description 1
• 229910006137 NiGe Inorganic materials 0.000 description 1
• 108091092724 Noncoding DNA Proteins 0.000 description 1
• 238000000636 Northern blotting Methods 0.000 description 1
• 101710163270 Nuclease Proteins 0.000 description 1
• 108091005461 Nucleic proteins Proteins 0.000 description 1
• 108700020497 Nucleopolyhedrovirus polyhedrin Proteins 0.000 description 1
• 239000004677 Nylon Substances 0.000 description 1
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
• 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
• 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 208000037273 Pathologic Processes Diseases 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 108010067902 Peptide Library Proteins 0.000 description 1
• 235000004347 Perilla Nutrition 0.000 description 1
• 244000124853 Perilla frutescens Species 0.000 description 1
• 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 241001518143 Polypodium <fern> Species 0.000 description 1
• 208000037062 Polyps Diseases 0.000 description 1
• 108010071690 Prealbumin Proteins 0.000 description 1
• 102000007584 Prealbumin Human genes 0.000 description 1
• 108010035746 Pregnancy Proteins Proteins 0.000 description 1
• 102000008217 Pregnancy Proteins Human genes 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
• 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 101710176177 Protein A56 Proteins 0.000 description 1
• ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
• 108020004518 RNA Probes Proteins 0.000 description 1
• 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
• 239000003391 RNA probe Substances 0.000 description 1
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
• 108700005075 Regulator Genes Proteins 0.000 description 1
• 241001068295 Replication defective viruses Species 0.000 description 1
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
• HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
• AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
• 101710141795 Ribonuclease inhibitor Proteins 0.000 description 1
• 229940122208 Ribonuclease inhibitor Drugs 0.000 description 1
• 240000000111 Saccharum officinarum Species 0.000 description 1
• 235000007201 Saccharum officinarum Nutrition 0.000 description 1
• 108091081021 Sense strand Proteins 0.000 description 1
• 101100018382 Shigella flexneri icsP gene Proteins 0.000 description 1
• 241000700584 Simplexvirus Species 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• 241000191940 Staphylococcus Species 0.000 description 1
• 108091081024 Start codon Proteins 0.000 description 1
• 241000194017 Streptococcus Species 0.000 description 1
• 235000021536 Sugar beet Nutrition 0.000 description 1
• 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
• 230000033540 T cell apoptotic process Effects 0.000 description 1
• 108091008874 T cell receptors Proteins 0.000 description 1
• 230000005867 T cell response Effects 0.000 description 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
• 206010042971 T-cell lymphoma Diseases 0.000 description 1
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
• NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
• 229910052771 Terbium Inorganic materials 0.000 description 1
• 206010043376 Tetanus Diseases 0.000 description 1
• 244000269722 Thea sinensis Species 0.000 description 1
• 108091036066 Three prime untranslated region Proteins 0.000 description 1
• 108010022394 Threonine synthase Proteins 0.000 description 1
• 108020004440 Thymidine kinase Proteins 0.000 description 1
• 102000009843 Thyroglobulin Human genes 0.000 description 1
• 241000723873 Tobacco mosaic virus Species 0.000 description 1
• 101710183280 Topoisomerase Proteins 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 101100244975 Trypanosoma cruzi (strain CL Brener) PLR-1 gene Proteins 0.000 description 1
• 108091023045 Untranslated Region Proteins 0.000 description 1
• 241000700618 Vaccinia virus Species 0.000 description 1
• 241000700647 Variola virus Species 0.000 description 1
• FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
• OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
• 238000002679 ablation Methods 0.000 description 1
• 150000001242 acetic acid derivatives Chemical class 0.000 description 1
• 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
• 230000021736 acetylation Effects 0.000 description 1
• 238000006640 acetylation reaction Methods 0.000 description 1
• 102000005421 acetyltransferase Human genes 0.000 description 1
• 108020002494 acetyltransferase Proteins 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 208000009621 actinic keratosis Diseases 0.000 description 1
• 210000001642 activated microglia Anatomy 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 230000010933 acylation Effects 0.000 description 1
• 238000005917 acylation reaction Methods 0.000 description 1
• 229960002964 adalimumab Drugs 0.000 description 1
• 229960000643 adenine Drugs 0.000 description 1
• 230000001070 adhesive effect Effects 0.000 description 1
• 210000001789 adipocyte Anatomy 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 230000006838 adverse reaction Effects 0.000 description 1
• 230000001270 agonistic effect Effects 0.000 description 1
• PPQRONHOSHZGFQ-LMVFSUKVSA-N aldehydo-D-ribose 5-phosphate Chemical group OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PPQRONHOSHZGFQ-LMVFSUKVSA-N 0.000 description 1
• OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
• 229930002945 all-trans-retinaldehyde Natural products 0.000 description 1
• SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
• 239000013566 allergen Substances 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 230000009435 amidation Effects 0.000 description 1
• 238000007112 amidation reaction Methods 0.000 description 1
• 229940126575 aminoglycoside Drugs 0.000 description 1
• STFSECMHVCFKFX-UHFFFAOYSA-N aminotin Chemical compound [Sn]N STFSECMHVCFKFX-UHFFFAOYSA-N 0.000 description 1
• BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
• 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
• 235000011130 ammonium sulphate Nutrition 0.000 description 1
• 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
• 238000004873 anchoring Methods 0.000 description 1
• 239000003098 androgen Substances 0.000 description 1
• 208000036878 aneuploidy Diseases 0.000 description 1
• 231100001075 aneuploidy Toxicity 0.000 description 1
• 238000005571 anion exchange chromatography Methods 0.000 description 1
• 238000000137 annealing Methods 0.000 description 1
• 230000003042 antagnostic effect Effects 0.000 description 1
• NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 230000002682 anti-psoriatic effect Effects 0.000 description 1
• 210000000612 antigen-presenting cell Anatomy 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 238000002802 antimicrobial activity assay Methods 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 239000003816 antisense DNA Substances 0.000 description 1
• 239000000074 antisense oligonucleotide Substances 0.000 description 1
• 238000012230 antisense oligonucleotides Methods 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 235000021016 apples Nutrition 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 230000010516 arginylation Effects 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 210000003567 ascitic fluid Anatomy 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 238000011888 autopsy Methods 0.000 description 1
• 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
• 229960004669 basiliximab Drugs 0.000 description 1
• 210000003651 basophil Anatomy 0.000 description 1
• 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
• 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
• 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
• DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
• 235000013734 beta-carotene Nutrition 0.000 description 1
• TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
• 239000011648 beta-carotene Substances 0.000 description 1
• 229960002747 betacarotene Drugs 0.000 description 1
• 229960002938 bexarotene Drugs 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 238000003766 bioinformatics method Methods 0.000 description 1
• 230000008512 biological response Effects 0.000 description 1
• 238000005460 biophysical method Methods 0.000 description 1
• 210000002459 blastocyst Anatomy 0.000 description 1
• 210000000601 blood cell Anatomy 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• 208000011803 breast fibrocystic disease Diseases 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 238000006555 catalytic reaction Methods 0.000 description 1
• 238000005277 cation exchange chromatography Methods 0.000 description 1
• 230000020411 cell activation Effects 0.000 description 1
• 239000006143 cell culture medium Substances 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 230000004709 cell invasion Effects 0.000 description 1
• 230000011748 cell maturation Effects 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 230000007248 cellular mechanism Effects 0.000 description 1
• 230000036755 cellular response Effects 0.000 description 1
• 239000013522 chelant Substances 0.000 description 1
• 125000003636 chemical group Chemical group 0.000 description 1
• 238000007385 chemical modification Methods 0.000 description 1
• 230000035605 chemotaxis Effects 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 108700010039 chimeric receptor Proteins 0.000 description 1
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
• VJYIFXVZLXQVHO-UHFFFAOYSA-N chlorsulfuron Chemical compound COC1=NC(C)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)Cl)=N1 VJYIFXVZLXQVHO-UHFFFAOYSA-N 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 239000013611 chromosomal DNA Substances 0.000 description 1
• 230000002759 chromosomal effect Effects 0.000 description 1
• 230000014107 chromosome localization Effects 0.000 description 1
• 238000011281 clinical therapy Methods 0.000 description 1
• 239000013599 cloning vector Substances 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 230000037319 collagen production Effects 0.000 description 1
• 229940047120 colony stimulating factors Drugs 0.000 description 1
• 238000010835 comparative analysis Methods 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 238000010668 complexation reaction Methods 0.000 description 1
• 239000003636 conditioned culture medium Substances 0.000 description 1
• 238000012790 confirmation Methods 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 239000003246 corticosteroid Substances 0.000 description 1
• 229960001334 corticosteroids Drugs 0.000 description 1
• 230000004940 costimulation Effects 0.000 description 1
• 230000000139 costimulatory effect Effects 0.000 description 1
• 238000012136 culture method Methods 0.000 description 1
• 210000004748 cultured cell Anatomy 0.000 description 1
• 235000012754 curcumin Nutrition 0.000 description 1
• 229940109262 curcumin Drugs 0.000 description 1
• 239000004148 curcumin Substances 0.000 description 1
• 125000000753 cycloalkyl group Chemical group 0.000 description 1
• UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
• 230000003436 cytoskeletal effect Effects 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
• SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
• 229960002806 daclizumab Drugs 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 229960003957 dexamethasone Drugs 0.000 description 1
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
• 229960002086 dextran Drugs 0.000 description 1
• 239000000032 diagnostic agent Substances 0.000 description 1
• 229940039227 diagnostic agent Drugs 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
• 102000038379 digestive enzymes Human genes 0.000 description 1
• 108091007734 digestive enzymes Proteins 0.000 description 1
• 239000012470 diluted sample Substances 0.000 description 1
• 239000000539 dimer Substances 0.000 description 1
• 206010013023 diphtheria Diseases 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• 239000012153 distilled water Substances 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 229960002311 dithranol Drugs 0.000 description 1
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
• 239000008298 dragée Substances 0.000 description 1
• 238000009509 drug development Methods 0.000 description 1
• 238000007878 drug screening assay Methods 0.000 description 1
• 238000002651 drug therapy Methods 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 235000013399 edible fruits Nutrition 0.000 description 1
• 229960000284 efalizumab Drugs 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 210000002308 embryonic cell Anatomy 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 239000006274 endogenous ligand Substances 0.000 description 1
• 210000005168 endometrial cell Anatomy 0.000 description 1
• 230000002357 endometrial effect Effects 0.000 description 1
• 230000009088 enzymatic function Effects 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 229960000403 etanercept Drugs 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 238000010195 expression analysis Methods 0.000 description 1
• 239000013613 expression plasmid Substances 0.000 description 1
• 210000003722 extracellular fluid Anatomy 0.000 description 1
• 210000001723 extracellular space Anatomy 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 230000003176 fibrotic effect Effects 0.000 description 1
• 230000004907 flux Effects 0.000 description 1
• 230000022244 formylation Effects 0.000 description 1
• 238000006170 formylation reaction Methods 0.000 description 1
• 238000013467 fragmentation Methods 0.000 description 1
• 238000006062 fragmentation reaction Methods 0.000 description 1
• 230000005714 functional activity Effects 0.000 description 1
• 238000002825 functional assay Methods 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 230000006251 gamma-carboxylation Effects 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 108091008053 gene clusters Proteins 0.000 description 1
• 238000001476 gene delivery Methods 0.000 description 1
• 230000009368 gene silencing by RNA Effects 0.000 description 1
• 238000012226 gene silencing method Methods 0.000 description 1
• 238000007429 general method Methods 0.000 description 1
• 230000007614 genetic variation Effects 0.000 description 1
• 210000004602 germ cell Anatomy 0.000 description 1
• 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
• 150000004676 glycans Chemical class 0.000 description 1
• 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
• 230000001456 gonadotroph Effects 0.000 description 1
• 239000002622 gonadotropin Substances 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 230000009931 harmful effect Effects 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 108060003552 hemocyanin Proteins 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
• 230000002363 herbicidal effect Effects 0.000 description 1
• 239000004009 herbicide Substances 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 150000002411 histidines Chemical class 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 150000003840 hydrochlorides Chemical class 0.000 description 1
• 230000033444 hydroxylation Effects 0.000 description 1
• 238000005805 hydroxylation reaction Methods 0.000 description 1
• 229960002591 hydroxyproline Drugs 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 230000036737 immune function Effects 0.000 description 1
• 230000003053 immunization Effects 0.000 description 1
• 230000005847 immunogenicity Effects 0.000 description 1
• 229960001438 immunostimulant agent Drugs 0.000 description 1
• 239000003022 immunostimulating agent Substances 0.000 description 1
• 230000003308 immunostimulating effect Effects 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• QNRXNRGSOJZINA-UHFFFAOYSA-N indoline-2-carboxylic acid Chemical compound C1=CC=C2NC(C(=O)O)CC2=C1 QNRXNRGSOJZINA-UHFFFAOYSA-N 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 229960000598 infliximab Drugs 0.000 description 1
• 230000010365 information processing Effects 0.000 description 1
• 238000013101 initial test Methods 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 239000002054 inoculum Substances 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 229960003786 inosine Drugs 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 230000016507 interphase Effects 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 238000007914 intraventricular administration Methods 0.000 description 1
• 230000026045 iodination Effects 0.000 description 1
• 238000006192 iodination reaction Methods 0.000 description 1
• 210000002510 keratinocyte Anatomy 0.000 description 1
• 210000003292 kidney cell Anatomy 0.000 description 1
• 229910052745 lead Inorganic materials 0.000 description 1
• 229960000681 leflunomide Drugs 0.000 description 1
• VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
• 235000021374 legumes Nutrition 0.000 description 1
• 108020001756 ligand binding domains Proteins 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 239000007791 liquid phase Substances 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 239000006194 liquid suspension Substances 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 150000004668 long chain fatty acids Chemical class 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 238000004020 luminiscence type Methods 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
• LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
• 235000009498 luteolin Nutrition 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 229960000274 lysozyme Drugs 0.000 description 1
• 239000004325 lysozyme Substances 0.000 description 1
• 235000010335 lysozyme Nutrition 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 239000006249 magnetic particle Substances 0.000 description 1
• 230000007257 malfunction Effects 0.000 description 1
• 150000002690 malonic acid derivatives Chemical class 0.000 description 1
• 210000001161 mammalian embryo Anatomy 0.000 description 1
• 210000005075 mammary gland Anatomy 0.000 description 1
• 230000008774 maternal effect Effects 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 229940126601 medicinal product Drugs 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000037353 metabolic pathway Effects 0.000 description 1
• 229910021645 metal ion Inorganic materials 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• 230000011987 methylation Effects 0.000 description 1
• 238000007069 methylation reaction Methods 0.000 description 1
• 244000000010 microbial pathogen Species 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 238000000520 microinjection Methods 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 235000010755 mineral Nutrition 0.000 description 1
• 239000000178 monomer Substances 0.000 description 1
• 210000003097 mucus Anatomy 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 238000002703 mutagenesis Methods 0.000 description 1
• 231100000350 mutagenesis Toxicity 0.000 description 1
• RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
• 229960004866 mycophenolate mofetil Drugs 0.000 description 1
• 230000007498 myristoylation Effects 0.000 description 1
• 229930014626 natural product Natural products 0.000 description 1
• 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
• 229960004927 neomycin Drugs 0.000 description 1
• 201000008383 nephritis Diseases 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 230000003448 neutrophilic effect Effects 0.000 description 1
• 239000002547 new drug Substances 0.000 description 1
• 230000009871 nonspecific binding Effects 0.000 description 1
• 238000010606 normalization Methods 0.000 description 1
• 230000031787 nutrient reservoir activity Effects 0.000 description 1
• 229920001778 nylon Polymers 0.000 description 1
• 102000052563 odorant-binding protein Human genes 0.000 description 1
• 108010000645 odorant-binding protein Proteins 0.000 description 1
• 239000002751 oligonucleotide probe Substances 0.000 description 1
• 229950010444 onercept Drugs 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
• 239000006179 pH buffering agent Substances 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 230000009054 pathological process Effects 0.000 description 1
• 230000006320 pegylation Effects 0.000 description 1
• 210000001322 periplasm Anatomy 0.000 description 1
• 210000003200 peritoneal cavity Anatomy 0.000 description 1
• 210000003245 peritoneal mesothelial cell Anatomy 0.000 description 1
• 238000002823 phage display Methods 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 239000012071 phase Substances 0.000 description 1
• 239000003016 pheromone Substances 0.000 description 1
• 235000021317 phosphate Nutrition 0.000 description 1
• 150000003905 phosphatidylinositols Chemical class 0.000 description 1
• 229940080469 phosphocellulose Drugs 0.000 description 1
• 150000008300 phosphoramidites Chemical class 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 230000035479 physiological effects, processes and functions Effects 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 239000013600 plasmid vector Substances 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 244000144977 poultry Species 0.000 description 1
• 201000011461 pre-eclampsia Diseases 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 230000002028 premature Effects 0.000 description 1
• 230000013823 prenylation Effects 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 230000037452 priming Effects 0.000 description 1
• 210000001236 prokaryotic cell Anatomy 0.000 description 1
• 230000009696 proliferative response Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• YIBNHAJFJUQSRA-YNNPMVKQSA-N prostaglandin H2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](O)CCCCC)[C@H]2C\C=C/CCCC(O)=O YIBNHAJFJUQSRA-YNNPMVKQSA-N 0.000 description 1
• 210000000064 prostate epithelial cell Anatomy 0.000 description 1
• 235000019419 proteases Nutrition 0.000 description 1
• 230000030788 protein refolding Effects 0.000 description 1
• 230000002797 proteolythic effect Effects 0.000 description 1
• 210000001938 protoplast Anatomy 0.000 description 1
• 230000001185 psoriatic effect Effects 0.000 description 1
• 229940043131 pyroglutamate Drugs 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 238000012113 quantitative test Methods 0.000 description 1
• 229960001285 quercetin Drugs 0.000 description 1
• 235000005875 quercetin Nutrition 0.000 description 1
• 230000006340 racemization Effects 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 210000003370 receptor cell Anatomy 0.000 description 1
• 108010003189 recombinant human tumor necrosis factor-binding protein-1 Proteins 0.000 description 1
• 230000015069 regulation of nervous system development Effects 0.000 description 1
• 230000027272 reproductive process Effects 0.000 description 1
• 210000004994 reproductive system Anatomy 0.000 description 1
• 208000017443 reproductive system disease Diseases 0.000 description 1
• 108091008146 restriction endonucleases Proteins 0.000 description 1
• 230000002207 retinal effect Effects 0.000 description 1
• NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
• 229930002330 retinoic acid Natural products 0.000 description 1
• 229960000342 retinol acetate Drugs 0.000 description 1
• 235000019173 retinyl acetate Nutrition 0.000 description 1
• 239000011770 retinyl acetate Substances 0.000 description 1
• 238000010839 reverse transcription Methods 0.000 description 1
• 239000003161 ribonuclease inhibitor Substances 0.000 description 1
• 210000003705 ribosome Anatomy 0.000 description 1
• 238000007363 ring formation reaction Methods 0.000 description 1
• 102220008330 rs199476310 Human genes 0.000 description 1
• 210000003296 saliva Anatomy 0.000 description 1
• 239000012266 salt solution Substances 0.000 description 1
• 101150067879 sas-6 gene Proteins 0.000 description 1
• 238000007790 scraping Methods 0.000 description 1
• 239000013049 sediment Substances 0.000 description 1
• 239000006152 selective media Substances 0.000 description 1
• 230000008786 sensory perception of smell Effects 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 230000009131 signaling function Effects 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 210000002460 smooth muscle Anatomy 0.000 description 1
• VMSRVIHUFHQIAL-UHFFFAOYSA-M sodium;n,n-dimethylcarbamodithioate Chemical compound [Na+].CN(C)C([S-])=S VMSRVIHUFHQIAL-UHFFFAOYSA-M 0.000 description 1
• 239000007790 solid phase Substances 0.000 description 1
• 210000001082 somatic cell Anatomy 0.000 description 1
• 101150022349 sopA gene Proteins 0.000 description 1
• 235000003687 soy isoflavones Nutrition 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 238000004611 spectroscopical analysis Methods 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 206010041823 squamous cell carcinoma Diseases 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 230000010473 stable expression Effects 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 235000013547 stew Nutrition 0.000 description 1
• 238000003756 stirring Methods 0.000 description 1
• 125000001424 substituent group Chemical group 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
• 238000006277 sulfonation reaction Methods 0.000 description 1
• 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
• 230000008093 supporting effect Effects 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 210000001179 synovial fluid Anatomy 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 229960001967 tacrolimus Drugs 0.000 description 1
• 229960000565 tazarotene Drugs 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• 150000003505 terpenes Chemical class 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
• 229940113082 thymine Drugs 0.000 description 1
• 229960002175 thyroglobulin Drugs 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 229960001727 tretinoin Drugs 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
• GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
• 229960001641 troglitazone Drugs 0.000 description 1
• 230000010245 tubular reabsorption Effects 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 238000010798 ubiquitination Methods 0.000 description 1
• 230000034512 ubiquitination Effects 0.000 description 1
• 241000712461 unidentified influenza virus Species 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 229940035893 uracil Drugs 0.000 description 1
• DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
• 229940045145 uridine Drugs 0.000 description 1
• 238000002255 vaccination Methods 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 230000029812 viral genome replication Effects 0.000 description 1
• 208000029257 vision disease Diseases 0.000 description 1
• 230000004393 visual impairment Effects 0.000 description 1
• 235000019155 vitamin A Nutrition 0.000 description 1
• 239000011719 vitamin A Substances 0.000 description 1
• NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
• 229940045997 vitamin a Drugs 0.000 description 1
• 235000012431 wafers Nutrition 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 238000009736 wetting Methods 0.000 description 1
• OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1